Rhythm Pharma Appoints Murray Stewart Chief Medical Officer

Xconomy Boston — 

Murray Stewart has been appointed chief medical officer of Rhythm Pharmaceuticals (NASDAQ: RYTM). Stewart joins Boston-based Rhythm from Novelion Therapeutics (NASDAQ: NVLN), where he was head of R&D. His experience also includes 18 years at GlaxoSmithKline (NYSE: GSK), where he held several roles, including chief medical officer. Last year, Rhythm raised $120 million in an IPO to finance continued work on setmelanotide, a late-stage drug candidate developed to treat genetic obesity disorders.